TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer
Condition(s):ESCCLast Updated:July 15, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):ESCCLast Updated:July 15, 2020Unknown status
Condition(s):Solid Tumor, AdultLast Updated:April 20, 2023Enrolling by invitation
Condition(s):Elevated Intraocular PressureLast Updated:May 25, 2022Active, not recruiting
Condition(s):HIV InfectionsLast Updated:February 14, 2024Active, not recruiting
Condition(s):Lung CancerLast Updated:September 13, 2021Unknown status
Condition(s):HIVLast Updated:July 19, 2023Recruiting
Condition(s):Colonic Diseases; Intestinal Disease; Gastrointestinal Disease; Digestive System DiseaseLast Updated:November 26, 2018Completed
Condition(s):HIV InfectionsLast Updated:July 18, 2018Completed
Condition(s):Acute Upper Gastrointestinal BleedingLast Updated:October 11, 2019Completed
Condition(s):Heart FailureLast Updated:March 12, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.